000			01467 a2200397 4500
005			20250517095954.0
264		0	_c20170206
008			201702s 0 0 eng d
022			_a1557-9859
024	7		_a10.1016/j.mcna.2016.03.014 _2doi
040			_aNLM _beng _cNLM
100	1		_aWright, Jennifer J
245	0	0	_aPharmacologic Therapy of Type 2 Diabetes. _h[electronic resource]
260			_bThe Medical clinics of North America _cJul 2016
300			_a647-63 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAging
650	0	4	_aBlood Glucose
650	0	4	_aBody Weight
650	0	4	_aDiabetes Mellitus, Type 2 _xcomplications
650	0	4	_aDipeptidyl-Peptidase IV Inhibitors _xtherapeutic use
650	0	4	_aDrug Administration Routes
650	0	4	_aGlucagon-Like Peptide 1 _xagonists
650	0	4	_aGlycated Hemoglobin
650	0	4	_aHumans
650	0	4	_aHypoglycemic Agents _xadministration & dosage
650	0	4	_aInsulin _xtherapeutic use
650	0	4	_aMetformin _xtherapeutic use
650	0	4	_aRenal Insufficiency _xepidemiology
650	0	4	_aSodium-Glucose Transporter 2 Inhibitors
650	0	4	_aSulfonylurea Compounds _xtherapeutic use
650	0	4	_aThiazolidinediones _xtherapeutic use
700	1		_aTylee, Tracy S
773	0		_tThe Medical clinics of North America _gvol. 100 _gno. 4 _gp. 647-63
856	4	0	_uhttps://doi.org/10.1016/j.mcna.2016.03.014 _zAvailable from publisher's website
999			_c26067995 _d26067995